Showing results (41-50 of 56) with videos related to
Sort By:
Pageof 6
The Annals of Thoracic Surgery|April 22, 2026
Acute Distal Limb Ischemia after Large-Bore Arterial Access: An Expert Review and Consensus RecommendationsRaghad Said, Michael P W Grocott, Courtney Maxey-Jones, et al.European Journal of Cancer (Oxford, England : 1990)|August 31, 2016
Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidineKelly E Huibregtse, Kieuhoa T Vo, Steven G DuBois, et al.Pediatric Blood & Cancer|May 23, 2014
Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II studyBrian Weiss, Brigitte C Widemann, Pamela Wolters, et al.BMJ Quality & Safety|September 6, 2015
Sustained reductions in time to antibiotic delivery in febrile immunocompromised children: results of a quality improvement collaborativeChristopher E Dandoy, Selena Hariharan, Brian Weiss, et al.Pediatrics|November 12, 2014
A team-based approach to reducing cardiac monitor alarmsChristopher E Dandoy, Stella M Davies, Laura Flesch, et al.Neuro-Oncology|October 16, 2014
Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II studyBrian Weiss, Brigitte C Widemann, Pamela Wolters, et al.Plos Genetics|December 21, 2016
Enrichment of Targetable Mutations in the Relapsed Neuroblastoma GenomeOlivia M Padovan-Merhar, Pichai Raman, Irina Ostrovnaya, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 16, 2012
Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trialKatherine K Matthay, Brian Weiss, Judith G Villablanca, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 3, 2015
131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II studyGregory A Yanik, Judith G Villablanca, John M Maris, et al.The New England Journal of Medicine|December 29, 2016
Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform NeurofibromasEva Dombi, Andrea Baldwin, Leigh J Marcus, et al.Pageof 6